Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It
Executive Summary
Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, Scrip offers a baker's dozen of possible drugs.
You may also be interested in...
Jardiance Improves Double-Digit Growth Potential With US Approval In CKD
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
First Round Of Drugs Up For Medicare Negotiation Gets Soft Landing
Big pharma valuations mostly held steady as CMS released its list of the first 10 drugs subject to Medicare negotiations under the Inflation Reduction Act, which held few surprises and included products nearing the end of their patent lives by the time negotiated pricing takes effect.
Tracking Industry’s Lawsuits Against IRA’s Medicare Price Negotiations
Industry stakeholders have filed various lawsuits against the US government, attempting to slow down or block the implementation of a new Medicare drug price negotiation program. Pink Sheet's new chart tracks the developments.